BSEM BioStem Technologies Inc (PK)

Caribbean International Holdings (Pink Sheets:CIHN) through its subsidiary, Regenerative BioScience, Inc., ("RBS") announced today that it is planning an addition to its website where the public may post questions about the Company's processes and facilities. Selected representative questions will be answered on a weekly basis by Dr. Leonel Liriano, the Company's Medical Director, and posted to the site.

Also, photographs taken during the World Congress in Orlando, FL this past weekend are available today on the Company's site. They include Dr. Leonel Liriano, the Company's Medical Director, the Company's Advisory Board Member, Rafael Gonzalez, Ph.D., the Company's CEO and Dr. Jesús Esparragoza, MD.

The Chairman and CEO of Caribbean International Holdings, stated, "We were quite impressed with Dr. Esparragoza, and we hope he will be able to accept our offer of a position on our Advisory Board in the near future."

Dr. Esparragoza, like Dr. Rafael Gonzalez, works for REHEALTH Regenerative Therapies (http://www.rehealth.com). Jesús Esparragoza, M.D. is a Fellow of American College of Cardiology. He graduated in 1977 from the Faculty of Medicine of the University Autónoma de Guadalajara, and acquired the title of Surgeon. He conducted his fellowship in Adult Cardiology at the Texas Heart Institute in Houston. He is also an Interventional Cardiologist.

He was a pioneer in stem cell therapies following approved protocols by COFEPRIS. He, in conjunction with several other doctors, made the first heart transplant in Guadalajara, Jalisco.

About The Company:

Caribbean International Holdings, Inc. is a holding company for Regenerative BioScience, Inc. ("RBS"). For more information about the Company or Dr. Leonel Liriano or Rafael Gonzalez, Ph.D. go to: http://www.regenerativebioscience.com/index.html  

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available on at http://www.sec.gov.

CONTACT: Investor Contact:
         BioScience
         (941) 924-9400